|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Pharmacological studies of a contraceptive drug Anordrin. |
| Chih-Ping K; Ming-Kang C; HSiu-Chuan C; Shih-HSing C; Ta-Wei P; Kang T |
| Scientia Sinica 18(2): 262-270. March-April 1975. |
| A pharmacological profile of a new oral contraceptive agent, Anordin (2epsilon, 17alpha-diethynyl, A-nor-androstane, |
| 2epsilon, 17beta-dihydroxydopropinate, AF-53), is presented. The drug is an A-nor-steroid with estrogenic activity |
| similar to that of ethinyl estradiol. Its has been shown to have considerable antifertility effect in rats, mice, rabbits, |
| hamsters and dogs. Repeated administration of Anordrin (AF-53) caused sterility in rats, but did not affect mating |
| behavior, and fertility soon returned after cessation of treatment. Administration of the drug terminated early |
| pregnancy in rats and rabbits. AF-53 significantly inhibited deciduoma formation in pseudopregnant rats (p less than |
| .01). AF-53 exerted synergistic action with small doses of progesterone and antagonistic action with large doses. |
| The drug showed no teratogenic effects with subminimal antifertility doses. AF-53 does not cause any apparent |
| abnormality in blood composition, renal and hepatic functions, and on the histologic picture of the organs. The peak |
| blood levels of the drug were usually found 9 hours after treatment, while urinary levels peaked between 10-12 hours. |
| AF-53 is also excreted in large amounts in the bile and feces. In clinical trials, the drug is administered postcoitally |
| only. The time of administration of AF-53 is not limited by the menstrual cycle, and does not need to be taken |
| continuously. (PubHealth.info Document ID: CONT7T 3047-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Pharmacological studies of a contraceptive drug Anordrin.", |
| is(are) Chih-Ping K; Ming-Kang C; HSiu-Chuan C; Shih-HSing C; Ta-Wei P; Kang T. The source of this article is |
| "Scientia Sinica 18(2): 262-270. March-April 1975.". This article was published in 1975 in English language(s). |
| (PubHealth.info® Document ID: CONT7T 3047-06. All rights reserved with PubHealth.info) PIN: 33047 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
